IMGT engineered variant nomenclature: IGHG variants

Citing this table: Lefranc, M.-P. and Lefranc, G., The Immunoglobulin FactsBook, Academic Press, London, UK (458 pages), 2001, ISBN:012441351X

1. Structural and biological properties of human immunoglobulins

2. Human immunoglobulin (IG) chain characteristics

3. IG interchain disulfide bridges per monomer

4. Lysines and cysteines of the Homo sapiens IGHG1, IGKC and IGLC1 and positions in the C-DOMAIN

5. Amino acid positions involved in ADCC, ADCP, CDC, half-life and half-IG exchange

7. Homo sapiens IGHG1 amino acids involved in the interactions with the C1q, FcγR and FCGRT

Species IMGT gene name IMGT engineered variant nomenclature IGHG gene variant description Property modifications
IMGT IGHG gene variant number hinge (h) or CH2 AA and IMGT position in h or CH2 of IGHG gene variant CH3 AA and IMGT position in CH3 of IGHG gene variant ADCC enhancement or reduction, ADCP enhancement, B cell inhibition CDC enhancement or reduction Half-IG exchange reduction, Half-life increase, Knobs-into-holes
Homo sapiens IGHG1 Homsap IGHG1v1 CH2 P1.4 v1 CH2 P1.4 ADCC reduction
Homsap IGHG1v2 CH2 V1.3 v2 CH2 V1.3 ADCC reduction
Homsap IGHG1v3 CH2 A1.2 v3 CH2 A1.2 ADCC reduction
Homsap IGHG1v4 CH2 A114 v4 CH2 A114 ADCC reduction CDC reduction
Homsap IGHG1v5 CH2 W109 v5 CH2 W109 ADCC reduction CDC enhancement
Homsap IGHG1v6 CH2 A85.4, A118, A119 v6 CH2 A85.4, A118, A119 ADCC enhancement
Homsap IGHG1v7 CH2 D3, E117 v7 CH2 D3, E117 ADCC enhancement
Homsap IGHG1v8 CH2 D3, L115, E117 v8 CH2 D3, L115, E117 ADCC enhancement CDC reduction
Homsap IGHG1v9 CH2 L7, P83, L85.2, I88; CH3 L83 v9 CH2 L7, P83, L85.2, I88 CH3 L83 ADCC enhancement
Homsap IGHG1v10 CH2 Y1.3, Q1.2, W1.1, M3, D30, E34, A85.4 v10 CH2 Y1.3, Q1.2, W1.1, M3, D30, E34, A85.4 ADCC enhancement
Homsap IGHG1v11 CH2 E34, D109, M115, E119 v11 CH2 E34, D109, M115, E119 ADCC enhancement
Homsap IGHG1v12 CH2 A1.1, D3, L115, E117 v12 CH2 A1.1, D3, L115, E117 ADCC enhancement
Homsap IGHG1v13 CH2 A1.1, D3, E117 v13 CH2 A1.1, D3, E117 ADCP enhancement
Homsap IGHG1v14 CH2 A1.3, A1.2 v14 CH2 A1.3, A1.2 ADCC reduction CDC reduction
Homsap IGHG1v14-1 CH2 A1.3, A1.2, A1 v14-1 CH2 A1.3, A1.2, A1 ADCC reduction CDC reduction
Homsap IGHG1v14-4 CH2 A1.3, A1.2, A114 v14-4 CH2 A1.3, A1.2, A114 ADCC reduction CDC reduction
Homsap IGHG1v14-48 CH2 A1.3, A1.2, R113 v14-48 CH2 A1.3, A1.2, R113 ADCC reduction CDC reduction
Homsap IGHG1v14-49 CH2 A1.3, A1.2, G114 v14-49 CH2 A1.3, A1.2, G114 ADCC reduction CDC reduction
Homsap IGHG1v14-67 CH2 A1.3, A1.2, S27 v14-67 CH2 A1.3, A1.2, S27 ADCC reduction CDC reduction
Homsap IGHG1v15 CH2 S118 v15 CH2 S118 CDC enhancement
Homsap IGHG1v16 CH2 W109, S118 v16 CH2 W109, S118 CDC enhancement
Homsap IGHG1v17 CH2 E29, F30, T107 v17 CH2 E29, F30, T107 CDC enhancement
Homsap IGHG1v18 CH3 R1, G109, Y120 v18 CH3 R1, G109, Y120 CDC enhancement
Homsap IGHG1v19 CH2 A34 v19 CH2 A34 CDC reduction
Homsap IGHG1v20 CH2 A105 v20 CH2 A105 CDC reduction
Homsap IGHG1v21 CH2 Y15.1, T16, E18 v21 CH2 Y15.1, T16, E18 Half-life increase
Homsap IGHG1v22 CH2 Y15.1, T16, E18; CH3 K113, F114, H116 v22 CH2 Y15.1, T16, E18 CH3 K113, F114, H116 Half-life increase
Homsap IGHG1v23 CH2 E1.2 v23 CH2 E1.2 ADCC reduction CDC reduction
Homsap IGHG1v24 CH3 L107, S114 v24 CH3 L107, S114 Half-life increase
Homsap IGHG1v25 CH2 E29, F113 v25 CH2 E29, F113 B cell inhibition
Homsap IGHG1v26 CH3 Y22 v26 CH3 Y22 Knob in knobs-into-holes interaction
Homsap IGHG1v27 CH2 C3 v27 CH2 C3 Site-specific drug attachment engineered cysteine
Homsap IGHG1v28 CH2 insC3A v28 CH2 insC3A Site-specific drug attachment engineered cysteine
Homsap IGHG1v29 CH2 A84.4 v29 CH2 A84.4 No N-glycosylation site
Homsap IGHG1v30 CH2 G84.4 v30 CH2 G84.4 No N-glycosylation site
Homsap IGHG1v31 CH3 T86 v31 CH3 T86 Hole in knobs-into-holes interaction
Homsap IGHG1v32 CH3 W22 v32 CH3 W22 Knob in knobs-into-holes interaction
Homsap IGHG1v33 CH3 S22, A24, V86 v33 CH3 S22, A24, V86 Hole in knobs-into-holes interaction
Homsap IGHG1v34 CH3 v34 CH3 G109 Favors hexamerisation
Homsap IGHG1v35 CH2 E29 v35 CH2 E29 CDC enhancement
Homsap IGHG1v36 CH2 Q84.4 v36 CH2 Q84.4 No N-glycosylation site
Homsap IGHG1v37 h S5 v37 h S5 No disulfide bridge inter H-L
Homsap IGHG1v38 CH2 S108, F113 v38 CH2 S108, F113 Abrogation of FcyRIII binding Abrogation of C1q binding
Homsap IGHG1v39 CH2 F1.3, E1.2, S116 v39 CH2 F1.3, E1.2, S116 ADCC reduction CDC reduction
Homsap IGHG1v40 CH2 A1.3, A1.2, S116 v40 CH2 A1.3, A1.2, S116 ADCC reduction CDC reduction
Homsap IGHG1v41 CH2 F1.3, E1.2 v41 CH2 F1.3, E1.2 ADCC reduction CDC reduction
Homsap IGHG1v42 CH2 Q14, CH3 L107 v42 CH2 Q14 CH3 L107 Half-life increase
Homsap IGHG1v43 CH2 A1.3, E1.2, A1 v43 CH2 A1.3, E1.2, A1 ADCC reduction CDC reduction
Homsap IGHG1v43-60 CH2 A1.3, E1.2, A1, S115, S116 v43-60 CH2 A1.3, E1.2, A1, S115, S116 ADCC reduction CDC reduction
Homsap IGHG1v44 CH2 C122 v44 CH2 C122 Site-specific drug attachment engineered cysteine
Homsap IGHG1v45 CH2 A1.1, L115, E117 v45 CH2 A1.1, L115, E117 ADCC and ADCP enhancement
Homsap IGHG1v46 CH3 K113, F114 v46 CH3 K113, F114 Half-life increase
Homsap IGHG1v47 CH2 delG1.1 v47 CH2 delG1.1 ADCC reduction
Homsap IGHG1v48 CH2 R113 v48 CH2 R113 ADCC reduction CDC reduction
Homsap IGHG1v49 CH2 G114 v49 CH2 G114 ADCC reduction CDC reduction
Homsap IGHG1v50 CH2 P1.4, V1.3, A1.2, delG1.1 v50 CH2 P1.4, V1.3, A1.2, delG1.1 ADCC reduction
Homsap IGHG1v51 CH2 K29 v51 CH2 K29 ADCC reduction CDC reduction
Homsap IGHG1v52 CH2 R1.1, R113 v52 CH2 R1.1, R113 ADCC reduction
Homsap IGHG1v53 CH2 F1.3, Q1.2, Q105 v53 CH2 F1.3, Q1.2, Q105 ADCC reduction CDC reduction
Homsap IGHG1v54 CH2 C83, C85 v54 CH2 C83, C85 Stabilizes CH2 in the absence of N84.4 glycosylation
Homsap IGHG1v55 CH2 C123 v55 CH2 C123 Site-specific drug attachment engineered cysteine
Homsap IGHG1v56 CH2 F85.2; CH3 F85.2 v56 CH2 F85.2 CH3 F85.2 Modified phenylalanine for conjugation
Homsap IGHG1v59 CH2 S1.3, T1.2, R1.1 v59 CH2 S1.3, T1.2, R1.1 Abrogation of FcyRIII binding Abrogation of C1q binding
Homsap IGHG1v60 CH2 S115, S116 v60 CH2 S115, S116 ADCC reduction CDC reduction
Homsap IGHG1v61 h S11 v61 h S11 No disulfide bridge inter H-H
Homsap IGHG1v62 h S14 v61 h S14 No disulfide bridge inter H-H
Homsap IGHG1v63 CH2 S2 v63 CH2 S2 ADCC reduction CDC reduction
Homsap IGHG1v64 CH2 C36 v64 CH2 C36 Site-specific drug attachment engineered cysteine
Homsap IGHG1v65 CH2 delE1.4, delL1.3, delL1.2 v65 CH2 delE1.4, delL1.3, delL1.2 ADCC reduction CDC reduction
Homsap IGHG1v66 CH2 A27 v66 CH2 A27 ADCC reduction
Homsap IGHG1v67 CH2 S27 v67 CH2 S27 ADCC reduction
Homsap IGHG1v68 CH3 V6, L22, L79, W81 v68 CH3 V6, L22, L79, W81 Enhances the heteropairing H-H of bispecific antibodies
Homsap IGHG1v69 CH3 V6, Y7,A85.1, V86 v69 CH3 V6, Y7,A85.1, V86 Enhances the heteropairing H-H of bispecific antibodies
Homsap IGHG1v70 h S5, S11, S14; CH2 S2 v70 h
CH2
S5, S11, S14
S2
ADCC reduction CDC reduction
Homsap IGHG1v71 CH2 A27, G116 v71 CH2 A27, G116 ADCC reduction CDC reduction
Homsap IGHG1v72 CH2 E37 v72 CH2 E37 ADCC reduction
Increases FcγRIIb binding
IGHG2
Homsap IGHG2v1 CH2 L1.3, L1.2, G1.1, G1 v1 CH2 L1.3, L1.2, G1.1, G1 ADCC enhancement
Homsap IGHG2v2 CH2 Q30, L92, S115, S116 v2 CH2 Q30, L92, S115, S116 ADCC reduction CDC reduction
Homsap IGHG2v3 CH2 A1.2, A1, S2, A30, L92, S115, S116 v3 CH2 A1.2, A1, S2, A30, L92, S115, S116 ADCC reduction CDC reduction
Homsap IGHG2v4 CH2 Q14 v4 CH2 Q14 Half-life increase
Homsap IGHG2v5 CH3 L107 v5 CH3 L107 Half-life increase
Homsap IGHG2v6 CH2 Q14, CH3 L107 v6 CH2 Q14 CH3 L107 Half-life increase
Homsap IGHG2v7 CH2 Y85.2, L92, A339 v7 CH2 Y85.2, L92, A339 ADCC reduction CDC reduction Reduction of acid-induced aggregation
Homsap IGHG2v8-1 CH2 A93 v8-1 CH2 A93 Half-life decrease
IGHG3 Homsap IGHG3v1 CH3 H115 v1 CH3 H115 Half-life increase
IGHG4
Homsap IGHG4v1 CH2 L1.3 v1 CH2 L1.3 ADCC enhancement
Homsap IGHG4v2 CH2 P116 v2 CH2 P116 CDC enhancement
Homsap IGHG4v3 CH2 E1.2 v3 CH2 E1.2 ADCC reduction CDC reduction
Homsap IGHG4v3-49 CH2 E1.2, G114 v3-49 CH2 E1.2, G114 ADCC reduction CDC reduction
Homsap IGHG4v4 CH2 A1.3, A1.2 v4 CH2 A1.3, A1.2 ADCC reduction CDC reduction
Homsap IGHG4v5 h P10 v5 h P10 Half-IG exchange reduction
Homsap IGHG4v6 CH3 K88 v6 CH3 K88 Half-IG exchange reduction
Homsap IGHG4v7 CH2 del 1.4, P1.3, V1.2, A1.1 v7 CH2 del 1.4, P1.3, V1.2, A1.1 ADCC reduction
Homsap IGHG4v8 CH3 R115, F116, P125 v8 CH3 R115, F116, P125 Abrogation of binding to Protein A
Homsap IGHG4v10 CH3 L85.1, K88 v10 CH3 L85.1, K88 Half-IG exchange reduction of bispecific IgG4
Homsap IGHG4v21 CH2 Y15.1, T16, E18 v21 CH2 Y15.1, T16, E18 Half-life increase
Homsap IGHG4v22 CH2 T16, P91, CH3 A114 v22 CH2 T16, P91 CH3 A114 Half-life increase
Homsap IGHG4v24 CH3 L107, S114 v24 CH3 L107, S114 Half-life increase
Homsap IGHG4v36 CH2 Q84.4 v36 CH2 Q84.4 No N-glycosylation site
Homsap IGHG4v37 CH2 P1.4, V1.3, A1.2, A27, V92 v37 CH2 P1.4, V1.3, A1.2, A27, V92 ADCC reduction CDC reduction
Homsap IGHG4v38 CH2 P1.4, V1.3, A1.2, G1.1del v38 CH2 P1.4, V1.3, A1.2, G1.1del ADCC reduction CDC reduction
Homsap IGHG4v49 CH2 G114 v49 CH2 G114 ADCC reduction CDC reduction
IGHG1-IGHG3
Homsap IGHG1G3v1 CH2 Q38, K40, F85.2 v1 CH2 Q38, K40, F85.2 CDC enhancement
IGHG2-IGHG4
Homsap IGHG2G4v1 CH2 delE1.4, P1.3, V1.2, A1.1 v1 CH2 delE1.4, P1.3, V1.2, A1.1 ADCC reduction CDC reduction
Mus musculus IGHG2B
Musmus IGHG2Bv1 CH2 L1.2 v1 CH2 L1.2 ADCC enhancement
Musmus IGHG2Bv2 CH2 A101 v2 CH2 A101 CDC reduction
Musmus IGHG2Bv3 CH2 A103 v3 CH2 A103 CDC reduction
Musmus IGHG2Bv4 CH2 A105 v4 CH2 A105 CDC reduction
Canis lupus familiaris IGHG2
Canlupfam IGHG2v1 CH2 A1.3, A1.2, A1 v1 CH2 A1.3, A1.2, A1 ADCC reduction CDC reduction
Canlupfam IGHG2v2 CH2 A1.3, A1.2, G114 v2 CH2 A1.3, A1.2, G114 ADCC reduction CDC reduction
Canlupfam IGHG2v29 CH2 A84.4 v29 CH2 A84.4 No N-glycosylation site
CNRS Université de Montpellier European Commission

© Copyright 1995-2024 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT